That is an encouraging article if we do take the go alone approach for HIV. The drug safety and simplified protocol for easier drug adherence, will help its cause. As known, seems the current financing situation is the biggest concern. Hopefully the PCa test will resolve this.

With such a large market potential and the likelihood they need this established for future indications, maybe the risk reward is worth it to go this route for HIV. Maybe initial launch and market penetration will be less than with an established BP, but the revenue to CYDY could still be more than that of the alternative royalty revenue.